First-Line Treatment for Strep Pharyngitis

Introduction to First-Line Treatment

The Infectious Diseases Society of America recommends penicillin V or amoxicillin for 10 days as the first-line treatment for strep pharyngitis, based on proven efficacy, safety, narrow spectrum of activity, and low cost 1

Penicillin remains the treatment of choice, with critically no documented cases of penicillin-resistant Group A Streptococcus worldwide 1
The American Academy of Pediatrics and the Infectious Diseases Society of America support the use of penicillin V, with dosing regimens of 250 mg four times daily or 500 mg twice daily for adolescents/adults for 10 days 1
Amoxicillin is often preferred over penicillin V in young children due to better palatability, with equal efficacy, and dosing regimens of 50 mg/kg once daily for children or 500 mg twice daily for adults, for 10 days 1, 2

A full 10-day course of penicillin or amoxicillin is mandatory to achieve maximal pharyngeal eradication of Group A Streptococcus and prevent acute rheumatic fever, supported by strong, high-quality evidence from the 2012 IDSA guidelines 1, 2

For non-immediate/non-anaphylactic penicillin allergy, first-generation cephalosporins are the preferred alternative, with strong, high-quality evidence, and dosing regimens such as cephalexin 500 mg twice daily for adults or cefadroxil 1 gram once daily for adults, for 10 days 1, 3
For immediate/anaphylactic penicillin allergy, clindamycin is the preferred choice, with strong, moderate-quality evidence, and dosing regimens of 300 mg three times daily for adults, for 10 days 1, 3
Macrolide alternatives, such as azithromycin and clarithromycin, are less preferred due to resistance concerns, with macrolide resistance rates of 5-8% in the United States 1, 3

The Infectious Diseases Society of America recommends avoiding trimethoprim-sulfamethoxazole, tetracyclines, and sulfonamides due to high resistance rates, and avoiding cephalosporins in patients with anaphylaxis, angioedema, or immediate urticaria to penicillin 1, 2, 3
The American Academy of Pediatrics and the Infectious Diseases Society of America advise against shortening treatment duration below 10 days, except for azithromycin's 5-day course, to prevent treatment failure and rheumatic fever risk 1, 2

The Infectious Diseases Society of America recommends acetaminophen or NSAIDs for moderate to severe symptoms or high fever, and advises against aspirin in children due to Reye syndrome risk, and against corticosteroids 1, 2

Routine follow-up throat cultures or rapid antigen detection tests are not recommended for asymptomatic patients who have completed therapy, but may be considered in special circumstances, such as patients with a history of rheumatic fever, as suggested by the Infectious Diseases Society of America 1, 3

The American Heart Association states that newer fluoroquinolones (e.g., levofloxacin, moxifloxacin) are active in vitro against Group A Streptococcus but are expensive, have an unnecessarily broad spectrum, and are not recommended for routine treatment of GAS pharyngitis (Class III, Level B evidence). 4
Older fluoroquinolones (e.g., ciprofloxacin) have limited activity against GAS and should not be used for GAS pharyngitis. 4

Penicillin or amoxicillin remains the drug of choice for streptococcal pharyngitis because of proven efficacy, safety, narrow antimicrobial spectrum, and low cost. (Supported by multiple clinical infectious disease references.) [5][6]

Clindamycin 300 mg orally three times daily for 10 days is the preferred choice; resistance among GAS isolates in the United States is approximately 1%. 4
Azithromycin 500 mg once daily for 5 days is an acceptable alternative, but macrolide resistance in the United States ranges from 5 % to 8%, making it less reliable. 4
Clarithromycin 250 mg twice daily for 10 days provides a comparable macrolide option with similar resistance concerns. 4

Trimethoprim‑sulfamethoxazole should not be used because sulfonamides fail to eradicate GAS in pharyngitis patients (Class III, Level B). 4
Tetracyclines are contraindicated due to a high prevalence of resistant GAS strains (Class III, Level B). 4
Cephalosporins must be avoided in patients with immediate (anaphylactic) penicillin hypersensitivity because cross‑reactivity risk can be up to 10%. 4

Employing broad‑spectrum antibiotics when narrow‑spectrum agents are appropriate increases cost and heightens selection pressure for antibiotic‑resistant flora without delivering superior efficacy for GAS eradication. 4